Ms Deborah A Becker, RN, CNS-PMH | |
205 Dental Dr Ste 3, Warner Robins, GA 31088-8210 | |
(478) 328-1620 | |
(478) 929-8801 |
Full Name | Ms Deborah A Becker |
---|---|
Gender | Female |
Speciality | Clinical Nurse Specialist - Psychiatric/mental Health, Adult |
Location | 205 Dental Dr Ste 3, Warner Robins, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1245571082 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
364SP0809X | Clinical Nurse Specialist - Psychiatric/mental Health, Adult | RN066734 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ms Deborah A Becker, RN, CNS-PMH 205 Dental Dr Ste 3, Warner Robins, GA 31088-8210 Ph: (478) 328-1620 | Ms Deborah A Becker, RN, CNS-PMH 205 Dental Dr Ste 3, Warner Robins, GA 31088-8210 Ph: (478) 328-1620 |
News Archive
The current study from Israel discusses the change in antibody response with the trimester of infection and the infecting variant.
Has your paternal or maternal grandfather broken their hip on any occasion? In that case there is a greater risk that your own bones are more fragile as an adult. This has been demonstrated in a thesis at the Sahlgrenska Academy, University of Gothenburg, Sweden based on a study of over 1,000 young adults in Gothenburg, which identified those factors increasing the risk of bone fragility in men.
Postoperative adhesions are a major complication in strabismus surgery. Amniotic membrane has been used in the hopes of preventing these adhesions by forming a biological barrier during healing. In an article in the December 2010 issue of the Journal of AAPOS, a team of researchers from Cairo University have discovered that the new approach may also have the opposite effect.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
› Verified 4 days ago